HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers.

AbstractPURPOSE:
Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-κB/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.
METHODS:
A total of 430 patients with breast cancer treated between 2006 and 2013 were retrospectively reviewed; of these, 123 cases were considered TNBC (n=71; 58%) or were positive for HER2 (n=52; 42%). Mesothelin expression was assessed by immunohistochemistry.
RESULTS:
Of the patients with TNBC, 30 (42.3%) were positive for mesothelin expression, compared to only two (3.8%) of the HER2-positive cases. As most HER2-positive tumors were negative for mesothelin staining, statistical analysis was not performed. Median overall survival (OS) was 70.1 months for patients with TNBC, whereas median OS was 70.1 months, in the mesothelin-positive group and 74.5 months in mesothelin-negative group, respectively. Strong correlation was seen between mesothelin expression and tumor grade in patients with TNBC (P<0.005). In a multivariable Cox proportional hazards model, mesothelin expression was not independently associated with OS in patients with TNBC.
CONCLUSIONS:
Expression of mesothelin was observed in 42.3% of patients with TNBC and demonstrated a strong association with tumor grade. However, its expression was not correlated with prognosis.
AuthorsIbrahim Vedat Bayoglu, Betul Bolat Kucukzeybek, Yuksel Kucukzeybek, Umut Varol, Ibrahim Yildiz, Ahmet Alacacioglu, Murat Akyol, Lutfiye Demir, Ahmet Dirican, Yasar Yildiz, Tarik Salman, Mustafa Oktay Tarhan
JournalBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie (Biomed Pharmacother) Vol. 70 Pg. 190-5 (Mar 2015) ISSN: 1950-6007 [Electronic] France
PMID25776500 (Publication Type: Journal Article)
CopyrightCopyright © 2015 Elsevier Masson SAS. All rights reserved.
Chemical References
  • Biomarkers, Tumor
  • GPI-Linked Proteins
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Mesothelin
Topics
  • Adult
  • Biomarkers, Tumor (biosynthesis)
  • Breast Neoplasms (diagnosis, metabolism, mortality)
  • Female
  • GPI-Linked Proteins (biosynthesis)
  • Humans
  • Mesothelin
  • Middle Aged
  • Prognosis
  • Receptor, ErbB-2
  • Survival Rate (trends)
  • Triple Negative Breast Neoplasms (diagnosis, metabolism, mortality)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: